Citius Oncology Reports Positive LYMPHIR Phase 1 CAR-T Data

An update from Citius Pharmaceuticals ( (CTXR) ) is now available.

On March 4, 2026, Citius Oncology reported positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR given before commercial CD19-directed CAR-T therapy in high-risk relapsed or refractory diffuse large B-cell lymphoma. The study, led by investigators at the University of Minnesota and City of Hope, found LYMPHIR well tolerated with no dose-limiting toxicities and demonstrated effective regulatory T-cell depletion when used to augment standard lymphodepletion.

Among 14 high-risk DLBCL patients, all of whom proceeded to CAR-T infusion with approved commercial products, the trial showed an 86% overall response rate at one month, including 57% complete and 29% partial responses, with one-year progression-free and overall survival of 77% and 84%, respectively. While not powered for definitive efficacy conclusions and using LYMPHIR outside its approved indication, the favorable safety profile and pharmacodynamic data support LYMPHIR’s potential to enhance CAR-T outcomes, reinforcing Citius Oncology’s strategy to expand the drug’s role beyond cutaneous T-cell lymphoma and potentially strengthening its position in the immuno-oncology market.

The most recent analyst rating on (CTXR) stock is a Hold with a $0.68 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Neutral.

The score is driven primarily by weak financial performance (large ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). A low-debt balance sheet provides some support, and the LYMPHIR launch is a notable positive catalyst, but current profitability and funding dependence keep the overall score low.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Oncology, Inc. is an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc., dedicated to developing and commercializing targeted cancer therapies. The company launched LYMPHIR, an FDA-approved treatment for relapsed or refractory Stage I–III cutaneous T-cell lymphoma, in the U.S. in December 2025 and estimates its initial, underserved market at more than $400 million, supported by orphan-drug protections and broader immuno-oncology IP.

Citius Oncology positions LYMPHIR as a platform asset in immuno-oncology, leveraging its regulatory T-cell–depleting mechanism in combination with other therapies. Management views its intellectual property portfolio, including trade secrets and pending patents for use with checkpoint inhibitors, as central to its competitive positioning in the targeted oncology segment.

Average Trading Volume: 792,253

Technical Sentiment Signal: Strong Sell

Current Market Cap: $16.56M

Find detailed analytics on CTXR stock on TipRanks’ Stock Analysis page.